Thermo Fisher Scientific Inc

TMO remains in a medium- and long-term uptrend, trading above its 50- and 200-day SMAs but is experiencing a corrective pullback. Short-term weakness is visible as price oscillates around the 9- and 20-day EMAs with RSI near neutral. We defer execution and stalk for a dip into the 9/20 EMA zone (~606–610) or a retest of the rising 50-day SMA (~578) for a higher-probability bullish entry. A decisive break below the 50-day SMA would invalidate the medium-term bullish bias.

• ↑Q2 revenue $11.99B (+10% YoY) and adjusted EPS $6.03 (+13%)
• ↑Raised full-year revenue guidance to $47.4–48.1B and EPS to $24.93–25.33
• ↓Customers cautious as academic/government budgets are unsettled for 2026